UBS Reaffirms Their Buy Rating on Novo Nordisk (0QIU)
Confident Investing Starts Here:
Walton covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Bayer, and Sanofi. According to TipRanks, Walton has an average return of -0.5% and a 52.08% success rate on recommended stocks.
In addition to UBS, Novo Nordisk also received a Buy from Deutsche Bank 's Emmanuel Papadakis in a report issued on May 27. However, on May 16, Berenberg Bank maintained a Hold rating on Novo Nordisk (LSE: 0QIU).
0QIU market cap is currently DKK2013.8B and has a P/E ratio of 19.73.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of 0QIU in relation to earlier this year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
2 cheap penny stocks for savvy investors to consider in August
Purchasing penny stocks can supercharge the growth prospects of an investor's portfolio. But issues like limited scale, inconsistent revenues, and thinner balance sheets — not to mention the added threat of share price volatility — can also make these small caps risky stocks to buy. Investors can manage the danger they take on, however, by snapping up penny shares that command low valuations. This pricing cushion can offer protection from share price drops if the company's growth plan doesn't pan out as expected. With this in mind, here are two top shares to consider this month. Screen idol The threat to cinema operators is severe as streaming companies like Netflix change the way we consume movies. Yet Everyman Media (LSE:EMAN) continues performing strongly, even as pressure on consumers' spending power persists. Everyman — which operates 48 theatres across the country — isn't your bog-standard multiplex owner. It offers a well-rounded experience, showing niche, independent, and foreign films alongside the usual blockbusters. What's more, patrons can grab a drink at its bars and go for a meal at its in-house restaurants, too, offering everything people need for a good night out. This value-added strategy is paying off handsomely. In the 26 weeks to 3 July, group revenues leapt 21%, to £56.5m. Admissions increased 15% from the same 2024 period; ticket prices rose 6%; and food and beverage spend per head was up 5.9%. Consequently, group EBITDA shot 33% higher over the period, to £8.2m. Everyman is confident its 'whole experience' model will continue delivering the goods, and is eyeing further expansion to its estate — it 'plans to open two additional venues in 2026', it's said, and enjoys 'a strong pipeline of future developments' too. Naturally, the ongoing streaming revolution will remain a threat to businesses like Everyman for the foreseeable future. But in the case of this penny stock, my view is the danger is more than baked into the cheapness of its shares. The screen idol's enterprise value (EV) to EBITDA (earnings before interest, tax, depreciation, and amortisation) ratio is just 2.8 times. Any reading below 10 suggests a share could be undervalued. Property for pennies The second top penny share to consider is Schroder European Real Estate Investment Trust (LSE:SERE). Unlike many small caps, it offers the possibility of a large passive income as well as growth, which reflects its classification as a REIT. Under sector rules, at least 90% of rental-related profits must be paid out in dividends each year. Please note that tax treatment depends on the individual circumstances of each client and may be subject to change in future. The content in this article is provided for information purposes only. It is not intended to be, neither does it constitute, any form of tax advice. That's all well and good on paper. But with eurozone economies struggling for growth and inflationary pressures persisting, the trust's returns could theoretically disappoint in the near term. Such dangers wouldn't necessarily put me off if I had cash to invest, however. Over the long term, the company — which owns retail, office, and industrial assets, among others — has the potential to deliver spectacular earnings growth. Its focus on 'winning' cities with strong economies, robust infrastructure, and attractive environments (like Paris and Berlin) gives it an edge achieving impressive rental income growth. And, today, the trust offers excellent all-round value. It trades at an 31.8% discount to its net asset value (NAV) per share. As for those dividends, its forward yield is an enormous 7.6%. The post 2 cheap penny stocks for savvy investors to consider in August appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
an hour ago
- Forbes
Sell HIMS Stock Ahead of Its Earnings?
Hims & Hers Health (NYSE:HIMS) is set to announce its earnings on Monday, August 4, 2025. Historically, HIMS stock has reacted unfavorably to earnings announcements. Since 2021, the stock has recorded a negative one-day return in 53% of instances after results. The median one-day decline has amounted to -5.8%, with a maximum one-day decrease of -22.3%. For traders focused on events, grasping these historical trends can be beneficial. While the actual results compared to consensus and expectations will be vital, there are two main strategies to contemplate: Analysts expect HIMS to report earnings of $0.23 per share on revenues of $552 million. This would mark substantial growth compared to the same quarter last year, which recorded earnings of $0.16 per share on revenues of $315 million. A possible positive factor for Hims & Hers' sales growth momentum is the reported underperformance of Novo Nordisk's weight loss medication in the U.S. due to the presence of compounded versions. Regarding fundamentals, HIMS has a market capitalization of $15 billion. Over the past twelve months, the company generated $1.8 billion in revenue and was operationally profitable, reporting $110 million in operating profits and a net income of $164 million. However, if you're looking for upside with less volatility than individual stocks, the Trefis High Quality portfolio offers an alternative — it has outperformed the S&P 500 and achieved returns exceeding 91% since its inception. Additionally, see – Is There More Upside For MSFT Stock? Review earnings reaction history of all stocks HIMS Stock Historical Likelihood of Positive Post-Earnings Return Here are some insights on one-day (1D) post-earnings returns: Additional information regarding the observed 5-Day (5D) and 21-Day (21D) returns post earnings is summarized along with the statistics in the table below. HIMS Stock Correlation Between 1D, 5D, and 21D Historical Returns A comparatively lower-risk strategy (though not effective if the correlation is weak) is to understand the relationship between short-term and medium-term returns post earnings, identify a pair that has the highest correlation, and perform the corresponding trade. For instance, if 1D and 5D exhibit the highest correlation, a trader can take a "long" position for the next 5 days if the 1D post-earnings return is positive. Here is some correlation information based on a 5-year and 3-year (more recent) timeframe. Note that the correlation 1D_5D denotes the relationship between 1D post-earnings returns and subsequent 5D returns. Discover more about the Trefis RV strategy that has outperformed its all-cap stocks benchmark (a blend of the S&P 500, S&P mid-cap, and Russell 2000), delivering strong results for investors. Additionally, if you seek upside with a smoother experience than an individual stock like Hims & Hers Health, consider the High Quality portfolio, which has surpassed the S&P and yielded >91% returns since its inception.
Business Insider
3 hours ago
- Business Insider
Salvatore Ferragamo S.p.A. (0P52) Gets a Hold from Kepler Capital
In a report released today, Charles-Louis Scotti from Kepler Capital maintained a Hold rating on Salvatore Ferragamo S.p.A., with a price target of €5.00. The company's shares closed yesterday at €4.89. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Scotti is ranked #8173 out of 9863 analysts. In addition to Kepler Capital , Salvatore Ferragamo S.p.A. also received a Hold from UBS's Chris Huang in a report issued today. However, on the same day, Barclays maintained a Sell rating on Salvatore Ferragamo S.p.A. (LSE: 0P52).
